Stephen Evans-freke
Non Executive Director
pharmaceutical sciences
adc therapeutics
Netherlands
Biography
Stephen Evans-Freke is Non Executive Director of ADC Therapeutics and Co-Founder and Managing General Partner of Auven Therapeutics. Mr. Evans-Freke has been associated with the biotechnology industry for over 35 years as an investment banker, asset manager, entrepreneur, company CEO, and venture capitalist. During the 1980s, he was lead investment banker to Genentech, AMGEN, Centocor, and a number of other leading biotech companies. During this period, Mr. Evans-Freke served as President of PaineWebber Development Corporation and later a member of PaineWebber Inc.'s Board of Directors. In 1990 Mr. Evans-Freke founded Selectide Corporation, where he served as Chairman until its sale to Hoechst in 1994. In 1991 he founded SUGEN, a drug discovery company, and served as Chairman and Chief Executive Officer through it’s IPO in 1995 until it’s sale to Pharmacia in 1999. Mr. Evans-Freke was also a co-founder of Fibrogen, Inc., Royalty Pharma AG, and CIBUS Global LLC, serving as Chairman of the latter until 2013. Mr. Evans-Freke serves on the 800th Anniversary Appeal Board of Cambridge University, from which he holds a Degree in Law, and also on the Board of the Christopher and Dana Reeve Foundation.
Research Interest
